Xeloda® XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda® have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8.
Two of the abstracts include data from the XeNA (Xeloda in NeoAdjuvant) trial, a study of Xeloda and docetaxel with or without Herceptin in patients with invasive breast cancer. The third presentation highlights findings that validate efficacy and cost benefits of Xeloda in breast cancer patients.
· Poster No. A54, [General Poster Session A, Sept. 7, 12:00 - 12:45 p.m.], “Frequency of circulating tumor cells (CTCs) in an open-label study of neoadjuvant capecitabine, docetaxel and trastuzumab (CDT) combination therapy in patients with HER2+ breast cancer (BC).” (Presenter: Stefan Glück)
· Poster No. 100, [General Poster Session C, Sept. 8, 7:00 - 8:00 a.m.], “Distribution of p53 mutations by AmpliChip assay in patients receiving neoadjuvant capecitabine (C) plus docetaxel (D) with or without trastuzumab (T) for newly diagnosed breast cancer (BC).” (Presenter: Nancy Patten)
· Poster No. A41, [General Poster Session D, Sept. 8, 11:45 a.m. - 12:45 p.m.], “Capecitabine is associated with fewer adverse events than other standard therapies in patients with breast cancer: a claims database analysis.” (Presenter: Hope Rugo, M.D.)
These studies affirm Roche’s commitment to exploring the expanded use of Xeloda in combination with new therapies.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.